SETD2 and nonpapillary renal cell carcinoma: Clinically in ccRCC, biallelic SETD2 alterations have been associated with adverse cancer-specific outcomes such as higher tumor stage, increased likelihood for recurrence or metastatic disease, and worse cancer-specific survival (11, 12).